RxDoctor Payments DataLook up a doctor →

Ali Valika, MD

Advanced Heart Failure and Transplant Cardiology · Elmhurst, ILNPI 1760696314

Payments from drug & device makers

$850,521in general payments, 2019–2025

Across 593 payments — averaging $1434.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$202K
  • Abbott$183K
  • Bayer$128K
  • AstraZeneca$85K
  • Procyrion, Inc.$70K
  • Boehringer Ingelheim$58K
  • plus $125K from 34 others

What the payments were for

  • Consulting fees$25,93512%
  • Speaking & faculty fees$163,70275%
  • Travel & lodging$11,1985%
  • Food & beverage$16,7508%
  • Education$2140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$850,521 in reported general payments places this provider in the 95th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.

See all advanced heart failure and transplant cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$320,147
Medicare patients
829
Services billed
2,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis114$2,688,328
UptraviSelexipag64$1,459,722
Tyvaso DpiTreprostinil50$1,198,222
CamzyosMavacamten97$799,127
OpsumitMacitentan59$735,533
JardianceEmpagliflozin600$635,627
EntrestoSacubitril/Valsartan424$552,484
AdempasRiociguat33$444,693
EliquisApixaban222$246,201
FarxigaDapagliflozin Propanediol156$138,060
XareltoRivaroxaban67$77,423
VeltassaPatiromer Calcium Sorbitex19$20,812
Ambrisentan11$19,278
Repatha SureclickEvolocumab26$18,289
CorlanorIvabradine Hcl18$16,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$14,944$2,934,529336 claims
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$201$2,195,255123 claims
E.r. Squibb & Sons, L.L.C.Camzyos$48,869$799,12797 claims
Boehringer IngelheimJardiance$58,464$635,627600 claims
NovartisEntresto$201,872$552,484424 claims
BayerAdempas, Kerendia$127,695$460,15847 claims
AstraZenecaFarxiga$85,081$138,060156 claims
Johnson & JohnsonXarelto$55$77,42367 claims
Novo NordiskWegovy, Ozempic$656$27,00524 claims
AmgenCorlanor$195$16,30418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.

Other advanced heart failure and transplant cardiology in Elmhurst

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →